- Home
- AZ vs PRTA Comparison
AZ vs PRTA Comparison
Compare AZ & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZ
- PRTA
- Stock Information
- Founded
- AZ 2018
- PRTA 2012
- Country
- AZ Canada
- PRTA Ireland
- Employees
- AZ N/A
- PRTA N/A
- Industry
- AZ Industrial Machinery/Components
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- AZ Industrials
- PRTA Health Care
- Exchange
- AZ Nasdaq
- PRTA Nasdaq
- Market Cap
- AZ 339.2M
- PRTA 366.6M
- IPO Year
- AZ N/A
- PRTA N/A
- Fundamental
- Price
- AZ $9.41
- PRTA $8.25
- Analyst Decision
- AZ Strong Buy
- PRTA Buy
- Analyst Count
- AZ 1
- PRTA 10
- Target Price
- AZ $20.00
- PRTA $24.29
- AVG Volume (30 Days)
- AZ 181.5K
- PRTA 1.0M
- Earning Date
- AZ 08-13-2025
- PRTA 08-04-2025
- Dividend Yield
- AZ N/A
- PRTA N/A
- EPS Growth
- AZ N/A
- PRTA N/A
- EPS
- AZ N/A
- PRTA N/A
- Revenue
- AZ $7,489,000.00
- PRTA $10,341,000.00
- Revenue This Year
- AZ $1,343,857.60
- PRTA N/A
- Revenue Next Year
- AZ N/A
- PRTA $122.46
- P/E Ratio
- AZ N/A
- PRTA N/A
- Revenue Growth
- AZ 19.04
- PRTA N/A
- 52 Week Low
- AZ $1.38
- PRTA $4.32
- 52 Week High
- AZ $12.36
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- AZ 40.41
- PRTA 75.08
- Support Level
- AZ $9.25
- PRTA $7.39
- Resistance Level
- AZ $10.22
- PRTA $8.17
- Average True Range (ATR)
- AZ 0.52
- PRTA 0.45
- MACD
- AZ -0.07
- PRTA 0.09
- Stochastic Oscillator
- AZ 13.27
- PRTA 95.07
About AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.